FDA issues how-to on drug-shortage management; Opioid debate may be hurting end-of-life patients;

@FiercePharma: Top-read in FiercePharmaManufacturing Thursday: $ACT production not meeting demand for new version of Alzheimer's drug. Article | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. More | Follow @EricPFierce

@CarlyHFierce: Legendary Genentech CEO Levinson cuts last ties with Roche. Story | Follow @CarlyHFierce

> The FDA has issued a new 24-page MAPP for how to report and manage drug shortages. MAPP (PDF)

> The U.S. and the EU have added $250 million to the pot to fight the Ebola outbreak after the World Health Organization said it had been hampered by budget cuts. Story

> Dutch civil servants decided to withhold from parliament information about negotiations it was having with drugmakers, including Boehringer Ingelheim. Story

Medical Device News

@FierceMedDev: Myriad's multigene predictive cancer test shows utility in new trial. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: Case hedges bets on brain device developer with a smartphone-based system for traumatic brain injuries. More from Bloomberg | Follow @EmilyWFierce

> Israeli colon capsule maker bucks M&A trend with plans for $60M IPO. News

> Researchers diagnose atrial fibrillation via webcam. Story

Biotech News

@FierceBiotech: EuroBiotech Report: AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015, more. More | Follow @FierceBiotech

@JohnCFierce: ICYMI - Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. Report | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Recro tanks after hitting the brakes on its lead pain drug. Story

> OncoMed gets back on track as FDA clears another clinical hold. Article

> Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. News

And Finally... A study suggests that the debate over opioids has kept some cancer patients from getting them even as their death nears. Story

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

AZ licenses COVID-19 vaccine to BioKangtai in China. Pfizer and BioNTech will supply 120 million doses of their shot to Japan. Legend CEO resigned.